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Abstract
Background:  Protein tyrosine phosphatases (PTPs) like their antagonizing protein tyrosine
kinases are key regulators of signal transduction thereby assuring normal control of cellular growth
and differentiation. Increasing evidence suggests that mutations in PTP genes are associated with
human malignancies. For example, mutational analysis of the tyrosine phosphatase (PTP) gene
superfamily uncovered genetic alterations in about 26% of colorectal tumors. Since in these studies
tumors have not been stratified according to genetic instability status we hypothesized that
colorectal tumors characterized by high-level of microsatellite instability (MSI-H) might show an
increased frequency of frameshift mutations in those PTP genes that harbor long mononucleotide
repeats in their coding region (cMNR).
Results: Using bioinformatic analysis we identified 16 PTP candidate genes with long cMNRs that
were examined for genetic alterations in 19 MSI-H colon cell lines, 54 MSI-H colorectal cancers,
and 17 MSI-H colorectal adenomas. Frameshift mutations were identified only in 6 PTP genes, of
which PTPN21 show the highest mutation frequency at all in MSI-H tumors (17%).
Conclusion: Although about 32% of MSI-H tumors showed at least one affected PTP gene, and
cMNR mutation rates in PTPN21, PTPRS, and PTPN5 are higher than the mean mutation frequency
of MNRs of the same length, mutations within PTP genes do not seem to play a common role in
MSI tumorigenesis, since no cMNR mutation frequency reached statistical significance and
therefore, failed prediction as a Positive Selective Target Gene.
Background
Chromosomal instability (CIN) and aneuploidy are
molecular features of most sporadic colorectal cancers
(~85%) and may confer a worse prognosis [1-3]. About
15% of colorectal cancers (CRC) show microsatellite
instability (MSI) due to defective DNA mismatch repair
(MMR; [4]). In hereditary non-polyposis colorectal cancer
(HNPCC/Lynch syndrome; about 5% of all CRC cases)
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most of the tumors display this MSI phenotype [5]. As a
common molecular theme, MMR-deficient MSI tumors of
the colon and other organs accumulate numerous inser-
tion/deletion mutations [6,7] not only at non-coding but
also at coding microsatellites (cMS) that cause transla-
tional frameshifts and abrogate normal protein function.
Such frameshift protein derived neo-peptides can be
highly immunogenic and are capable to induce cytotoxic
T-cell-mediated killing of MSI-H tumor cells in vitro [8-
11]. Frameshift mutations in cMS sequences of a large
number of candidate genes have been identified [12-16]
and mutations in some of them (TGFBR2, ACVR2, BAX;
TCF-4) appear to provide a growth advantage to affected
cells [17-20]. Both, sporadic and HNPCC-associated
colorectal MSI-H cancers, show distinct clinico-patholog-
ical characteristics that include frequent proximal site,
diploidy, poor differentiation, less distant metastases, per-
itumoral lymphocytic infiltrate, comparably good prog-
nosis, and altered chemoresponsiveness [6,7,21-26].
Increasing evidence suggests that cMS mutations in a lim-
ited number of target genes appear to be selected for dur-
ing MSI carcinogenesis and might account for some of
these clinico-histopathological features.
Protein tyrosine phosphatases (PTPs) like their antagoniz-
ing protein tyrosine kinases are key regulators of signal
transduction thereby assuring normal control of cellular
growth and differentiation [27]. Alterations in the delicate
balance between tyrosine phosphorylation and dephos-
phorylation contribute to the pathogenesis of different
inherited or acquired human diseases including autoim-
munity, diabetes, and cancer [27-29]. Several studies indi-
cate that mutations in PTP genes may be involved in
colorectal carcinogenesis. For example, increased PTPRA
mRNA levels have been observed in late stage colorectal
tumors [30] and frequent overexpression of the human
transmembrane-type PTP SAP-1 may occur relatively late
in the adenoma-carcinoma sequence [31]. Expression
profiling studies also suggested that PTPs appear to be
involved in metastasis of colorectal cancer [32]. In a simi-
lar approach, differential expression of the human
PTPN21 gene was observed when comparing MSI-H with
microsatellite stable (MSS) colorectal cancer cell lines [33]
and mutations in this gene were reported to occur in a
subset of MSI-H colorectal carcinomas [34]. Additionally,
a somatic mutation in the non-receptor PTP Shp2,
encoded by the PTPN11 gene, has been detected in a sin-
gle colon tumor with an increased frequency of somatic
alterations, but without microsatellite instability [35].
Moreover, identification of the murine PTP gene Ptprj as
a modifier locus conferring susceptibility to colorectal
cancer also led to the detection of frequent deletions of
the human PTPRJ  gene in primary colon cancers [36].
Finally, systematic mutational analysis of the human PTP
gene super family identified somatic mutations in six
PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14),
affecting 26% of colorectal cancers [37].
However, whether coding mononucleotide repeats
(cMNR) in PTP genes are specific targets of frameshift
mutations in MMR-deficient colorectal tumors is still
unknown. In the present study we identified 16 human
PTP genes harboring coding region microsatellites and
determined their mutation frequencies in MSI-H colorec-
tal tumors. About 32% of MSI-H tumors showed
frameshift mutations in any of these PTP genes. However,
gene-specific cMNR mutation frequencies did not reach
statistical significance according to our recently proposed
model for Selective Target Gene prediction [16]. Hence,
there is no significant statistical support for a common
involvement of any of these PTP genes in MSI colon car-
cinogenesis.
Methods
Cell Lines and Tumor Tissues
Most of the cell lines analyzed in the present study have
been described previously [15]. Additional human color-
ectal cancer cell lines were obtained from Cell Line Serv-
ices (CLS), Heidelberg, Germany (Colo94H, Colo205,
HCT8, SW1116, SW403, T84) or kindly provided by Dr.
M. Brattain, University of Texas, Health Science Center,
San Antonio, TX (CBS, FET), Dr. J. Wilson, Case Western
Reserve University, Cleveland, Ohio (Vaco5, Vaco6,
Vaco432, Vaco457), or Dr. I. Fidler (KM12). Cells were
grown in RPMI supplemented with 10% fetal calf serum
(Life Technologies, Karlsruhe, Germany). Formalin-fixed
and Paraffin-embedded tumor and matched normal
mucosae samples were treated as described [38]. The MSI
status of tumor cell lines (19 MSI-H, 17 MSS), primary
colorectal tumors (54 MSI-H and matched normal
mucosae), and colorectal adenomas (17 MSI-H, 6 MSS,
and matched normal mucosae) has been determined
using the NCI/ICG-HNPCC microsatellite marker panel
[39] as previously described [38]. Whole blood DNA sam-
ples of 60 healthy donors served as additional MSS con-
trols. Informed consent was obtained from all patients
and blood donors.
Candidate cMNR Sequences in PTP Genes
Human PTP genes were sought in our cMNR database
([15] accessible at http://www.seltarbase.org,
MNR_ensembl) that covers all human candidate coding
mononucleotide repeats in the entire human genome
annotated in the Ensembl database (Ensembl 19.34b,
2004). Candidate cMNRs with repeat length of at least 7
repeat units were considered for further analysis.
cMNR Instability Analysis
Primer design, DNA fragment and data analysis was per-
formed as described [40]. Primer sequences and anneal-BMC Cancer 2008, 8:329 http://www.biomedcentral.com/1471-2407/8/329
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ing temperatures are shown in Table 1 [see Additional file
1]. Frameshift mutations were verified by DNA sequence
analysis.
Results
cMNR instability of PTPs in MSI-H colorectal cancer cell 
lines
A candidate set of 16 PTP genes that contained cMNR
sequences composed of at least 7 repeat units were
retrieved from our cMNR database (Table 1 [see Addi-
tional file 1], MNR_ensembl is accessible at http://
www.seltarbase.org). Using DNA fragment analysis we
examined cMNR length alterations of these candidate
genes in 19 MSI-H and 17 MSS colorectal cancer cell lines.
cMNR frameshift mutations occurred exclusively in MSI-
H colorectal cancer cell lines and affected four PTP genes
(Tables 2 and 4 [see Additional file 1]; PTPN21, PTPN13,
PTPRS, PTPN23). Results of fragment analysis are exem-
plarily shown in figure 1. The highest mutation frequen-
cies were associated with the A8 cMNRs in PTPN13 (22%)
and PTPN21 (26%). All mutations occurred in a hetero-
zygous state and predominantly represented single nucle-
otide deletions (minus 1 allele, n = 10). Two were single
nucleotide insertions (plus 1 allele, PTPN13  and
PTPN21). No larger shifts could be detected. Overall, the
larger fraction of MSI-H colorectal cancer cell lines (63%;
12/19) showed frameshift mutations in any of the four
affected PTP genes.
PTP cMNR Mutations in MSI-H Primary Colorectal 
Carcinomas
We next analyzed the same set of 16 PTP genes for cMNR
frameshift mutations in 54 MSI-H colorectal carcinomas
and adjacent normal mucosa. Frameshift mutations in
Electropherograms of allelic shifts Figure 1
Electropherograms of allelic shifts. Electropherograms of shifted alleles. DNA fragment analysis of a representative set of 
PTP cMNRs in a MSI-H colorectal tumor (KS2966A, Sam49) and MSI-H cancer cell lines (Co115, TC71, and HCT116). Corre-
sponding wildtype alleles (wt, lower panel) are indicated together with tumor cell-specific allelic shifts marked by asterisks 
(upper panel). Allele intensities were determined (peak area) and ratios (f) of wildtype and novel alleles in primary tumors and 
cell lines were calculated, defining a 2-fold difference as threshold for allelic shifts.
* *
* * *BMC Cancer 2008, 8:329 http://www.biomedcentral.com/1471-2407/8/329
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these primary tumors were identified in 6 PTP genes
(PTPN21, PTPRS, PTPN5, PTPN23, PTPRA, PTPRE) com-
prising mutation targets shared by (PTPN21,  PTPRS,
PTPN23) or different from (PTPN5, PTPRA, PTPRE) those
in the MSI-H cell lines (Tables 3 and 4 [see Additional file
1], Figure 1). In MSS mucosa samples such changes
almost never occurred (1/703 analyses). Two genes,
PTPN21 and PTPRS, were most frequently affected in pri-
mary colorectal tumors (16% and 12%, respectively).
However, primary tumors lacked frameshift mutations in
the A8 repeat of PTPN13 and thus appeared to arise only
in cultured MSI-H CRC cell lines. Since LS174T and LS180
are derived from the same primary tumor [41,42] and the
overall mutation frequency is quite low it is very likely
that this mutation already manifested within the primary
tumor. Vice versa, mutations in three other PTPs (PTPN5,
PTPRA,  PTPRE) remained restricted to primary tumors
and occurred at very low frequency (Tables 3 and 4 [see
Additional file 1]). Overall, frameshift mutations in any of
these 6 PTP genes were observed in 32% of MSI-H tumors.
The most common type of mutation were single nucle-
otide deletions (16/21, 76%) and all frameshift muta-
tions appeared to affect only one allele (heterozygous).
Interestingly, all PTP mutations are located within or
upstream of the phosphatase domains and hence are
expected to impair or completely abrogate phosphatase
activity (Figure 2).
PTPN21 cMNR Mutations in MSI-H Colorectal Adenomas
Since mutations in the A8 coding repeat of PTPN21 were
the most frequent genetic alterations shared by MSI-H
cancer cell lines and primary tumors we also analyzed this
coding repeat in 17 MSI-H and 6 MSS colorectal adenoma
samples. As expected, no cMNR frameshift mutations
Domain structure of selected PTPs and sites of cMNR frameshift mutations Figure 2
Domain structure of selected PTPs and sites of cMNR frameshift mutations. Structure of PTP proteins. Tyrosine 
phosphatase domains (PTPc) as well as frameshift mutation sites (arrowhead, stippled lines) are indicated. Remaining domain 
abbreviations: IG immunoglobulin like domain, FN fibronectin type 3 domain, KIND kinase non-catalytic C-lobe domain, ERM 
ezrin/radixin/moesin domain, PDZ Domain present in PSD-95, Dlg, and ZO-1/2., BRO1 BRO1-like domain, TM transmem-
brane domain. Despite PTPN5 is a non-receptor phosphatase there is a TM domain annotated within Ensembl.
PTPN21 PTPc ERM
PTPN23
PTPc BRO1
PTPRS
PTPN5
TM PTPc
PTPRE
PTPRA
TM PTPc PTPc
TM PTPc PTPc
PTPc ERM PDZ PDZ PDZ PDZ PDZ KIND PTPN13
FN FN FN FN FN FN FN TM PTPc PTPc IG IG IG FNBMC Cancer 2008, 8:329 http://www.biomedcentral.com/1471-2407/8/329
Page 5 of 8
(page number not for citation purposes)
were detected in the MSS adenomas. However, in 2 of 17
MSI-H adenomas we identified deletion and insertion
mutations (Table 4 [see Additional file 1], Figure 1). These
results rather argue for an early event during MSI colorec-
tal carcinogenesis.
Discussion
The goal of this study was to determine type, frequency,
and pattern of cMNR frameshift mutations in protein PTP
genes in MSI-H colorectal cancer cell lines and primary
colon tumors. This gene family was selected because PTPs
are expected to exert tumor suppressive function and thus
represent potential targets of inactivating mutations in
DNA mismatch repair deficient tumors. Among the large
number of PTP genes in the human genome we selected
16 PTP genes that contained coding region microsatellites
of increased length (≥ 7 repetitive units). Our results pro-
vide evidence for frameshift mutations in six of these PTP
genes (PTPN21, PTPRS, PTPN5, PTPN23, PTPRA, PTPRE)
affecting about 32% of MSI-H colorectal cancers. This fre-
quency differs slightly from a previous study that reported
PTP mutations in 26% of unselected colorectal carcino-
mas [37]. Although most of the coding repeat-harboring
PTP genes (13/16 candidates) analyzed by us have also
been examined by Wang and co-workers, different sets of
mutated PTP genes were identified in both studies. In par-
ticular, we observed tumor-specific genetic alterations in
PTPN21,  PTPN23,  PTPN5,  PTPRA,  PTPRE  and  PTPRS
whereas mutations reported by Wang et al. were confined
to PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, and PTPN14.
This difference most probably can be explained by the dif-
ferent screening strategies used in these two studies. Wang
et al. performed their initial mutational pre-screening on
a set of 18 unselected colorectal tumors, This subset
would be expected to include only 2 to 3 MSI tumors
based on a general MSI frequency of 15% reported for
unselected colorectal cancers. Since the type of mutation
and the spectrum of affected genes is remarkably different
among MSS and MSI-H tumors, the observed differences
are not unexpected. However, there were also some con-
sistent findings in both studies. For example, PTPN13 was
examined by both groups but no cMNR mutations were
observed in a cumulative number of 69 MSI-H CRC sam-
ples ([43] and data presented here). Interestingly, Wang et
al. described two nonsense or frameshift mutations at the
expected MNR position within PTPN13. Unfortunately,
any information about the MSI status of these tumors is
missing. So, our investigation represent a reasonable com-
pletion of a systematic analysis of human PTP genes in
human colorectal cancers.
Recently, we proposed a statistical model that allows to
predict positively or negatively selected target genes of
MSI tumorigenesis in an organ-specific manner based on
cMNR mutation frequencies [16]. According to the actual
release of this model (http://www.seltarbase.org, release
200711), cMNRs of 7 or 8 repetitive units – in the absence
of any biological selection pressure – are expected to show
a mean somatic mutation rate of about 4% and 9%
respectively. In order to qualify as positively selected MSI
target genes, tumor-specific mutation frequencies for
c M N R s  o f  t h i s  l e n g t h  h a v e  t o  e x c e e d  2 2 %  a n d  2 8 % ,
respectively. The three most frequently mutated PTPs
identified in the present study (PTPN21 [A8], PTPRS [C7],
PTPN5 [C7]) show mutation frequencies of 17%, 12%,
and 6%, respectively. The final overall mutation fre-
quency of PTPN21  A8 (14.4%) is even slightly lower,
when considering data from the literature [14]. Certainly,
we did not extend our mutation search to the entire cod-
ing sequence of each PTP gene, and therefore, additional
mutations outside the cMNR sequence cannot be
excluded. Furthermore, detailed studies of individual
tumor types have provided compelling evidence that
mutations of different genes but within the same pathway
can have similar functional effects, i.e. leading to its dis-
ruption and providing a growth advantage to affected cells
[37], as it has been proposed for apoptotic genes like Fas,
Apaf-1, and Bcl-10  [44]. In conclusion, although these
gene-specific mutation rates are higher than the mean
mutation frequencies for this length of repeats they do not
reach statistical significance and prediction about positive
Selective Target Genes in MSI-H tumorigenesis is not fea-
sible. Therefore, human PTP genes do not seem to play a
common role in MSI-H tumorigenesis. However, contri-
bution to individual tumor development cannot be
excluded. Furthermore, the observation of 2 mutations
within a set of 17 MSI-H adenomas in PTPN21 argues for
an early event in malignant transformation.
Despite some structural diversity, the six PTP proteins
found to be mutated in the present study share a catalyti-
cally active phosphatase that resides in one (PTPN21,
PTPN23,  PTPN5,  PTPRS) or two (PTPRA) C-terminal
domains [45]. Notably, all cMNR frameshift mutation
sites are located upstream or within the first half of these
catalytic domains (see Figure 2) resulting in truncated
proteins that are expected to show partial or complete loss
of phosphatase activity. However, all PTP frameshift
mutations only affected a single allele leaving the cMNR
on the remaining allele intact. The presence of contami-
nating normal inflammatory cells in these tumors may
well account for this observation. Alternatively, the
remaining wildtype copy may be silenced by epigenetic
mechanisms. The absence of biallelic mutations in the
analyzed tumors could be due to a dominant negative
fashion or affection of gene dosage [46,47]. Shortened
transcripts of murine PTPs lacking catalytic or interaction
domains by alternative splicing can act in a dominant neg-
ative manner [48].BMC Cancer 2008, 8:329 http://www.biomedcentral.com/1471-2407/8/329
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From our analysis of preneoplastic lesions we further con-
clude that PTPN21  frameshift mutations also occur in
MSI-H colorectal adenomas albeit at lower frequency
(12%) thereby indicating an early step during MSI tumor-
igenesis. At the protein level, PTPN21 is known to bind to
and activate c-Src and Etk protein kinases [49,50]. Inter-
estingly, activated Etk has been reported to trigger apopto-
sis in breast cancer cells via Stat1 and p21 [51]. By
analogy, we hypothesize that inactivation of PTPN21 by
cMNR frameshift mutations in MSI-H colon cancer cells
might lead to Etk inactivation and subsequent inhibition
of apoptosis.
Conclusion
The work presented here shows a systematic investigation
using an evidence based approach: cMNRs of human PTP
genes with the highest chance for mutational events in
MSI-H colorectal tumors were selected. Although we
observed a similar overall mutation frequency in MSI
colorectal cancers compared to the results reported by
Wang et al. for unselected colorectal cancers, a different
set of PTP genes appears to be mutated in MSI tumors.
Human PTP genes identified in the present study seem to
play no common role in the tumorigenesis of MSI-H
tumors, supported by statistical considerations. However,
within individual MSI-H carcinogenesis such mutations
could have had impact to malignant transformation, but
so far no functional data exist that could confirm this
hypothesis.
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Note
Table 1: Coding microsatellites in candidate PTP genes
examined in this study.
For each of the 16 PTPs is given the official HUGO identi-
fication (hugoID), the actual Ensembl entry ID at http://
www.ensembl.org/Homo_sapiens (ENSG), the chromo-
somal localization (Chr.), the former EMBL accession
number (Acc. no.), the type of tract (nucleotide and
length, cMNR), the exact position of the tract in relation
to the sequence of the EMBL entry (Pos.), the annealing
temperature for PCR (Ta) as well as the primer sequences
(5' -> 3', sense and antisense) used for fragment analysis
of the respective tract.
Table 2: Allelic cMNR mutation status in MSI-H colorec-
tal cancer cell lines.
Wild type: wt; Deletions of one or two mononucleotides:
-1, -2; Insertions of one or two mononucleotides: +1, +2;
Analysis failed or not evaluable: 0.
Table 3: Allelic cMNR mutation status in MSI-H colorec-
tal carcinomas.
For abbreviations see legend of Table 2.
Table 4:  PTP cMNR mutation frequencies in MSI-H
colorectal cancer cell lines, tumors, and adenomas*.
*Analysis restricted to PTPN21.
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